Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
human vacines & immunotherapeutics
;
17(9): 1-5, 2021.
Article
in English
| LILACS, CONASS, ColecionaSUS, SES-SP, SESSP-IALPROD, SES-SP
| ID: biblio-1417874
ABSTRACT
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
COVID-19 Vaccines
/
SARS-CoV-2
/
Immunity, Cellular
/
Antigens
/
Neisseria meningitidis
Language:
English
Journal:
Human vacines & immunotherapeutics
Year:
2021
Type:
Article
Institution/Affiliation country:
Animal Health Department, Embrapa Southern Region Animal Husbandry/BR
/
Department of Immunology/BR
Similar
MEDLINE
...
LILACS
LIS